Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions
Abstract Drug–drug interactions (DDIs) occur commonly and may lead to severe adverse drug reactions if not handled appropriately. Considerable information to support clinical decision making regarding potential DDIs is available in the literature and through various systems providing electronic decision support for healthcare providers. The challenge for the prescribing physician lies in sorting out the evidence and identifying those drugs for which potential interactions are likely to become clinically manifest. P-glycoprotein (P-gp) is a drug transporting protein that is found in the plasma membranes in cells of barrier and elimination organs, and plays a role in drug absorption and excretion. Increasingly, P-gp has been acknowledged as an important player in potential DDIs and a growing body of information on the role of this transporter in DDIs has become available from research and from the drug approval process. This has led to a clear need for a comprehensive review of P-gp-mediated DDIs with a focus on highlighting the drugs that are likely to lead to clinically relevant DDIs. The objective of this review is to provide information for identifying and interpreting evidence of P-gp-mediated DDIs and to suggest a classification for individual drugs based on both in vitro and in vivo evidence (substrates, inhibitors and inducers). Further, various ways of handling potential DDIs in clinical practice are described and exemplified in relation to drugs interfering with P-gp..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Drugs - 77(2017), 8 vom: 05. Apr., Seite 859-883 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lund, Marie [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s40265-017-0729-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR033220158 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033220158 | ||
| 003 | DE-627 | ||
| 005 | 20230519195042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-017-0729-x |2 doi | |
| 035 | |a (DE-627)SPR033220158 | ||
| 035 | |a (SPR)s40265-017-0729-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Lund, Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Drug–drug interactions (DDIs) occur commonly and may lead to severe adverse drug reactions if not handled appropriately. Considerable information to support clinical decision making regarding potential DDIs is available in the literature and through various systems providing electronic decision support for healthcare providers. The challenge for the prescribing physician lies in sorting out the evidence and identifying those drugs for which potential interactions are likely to become clinically manifest. P-glycoprotein (P-gp) is a drug transporting protein that is found in the plasma membranes in cells of barrier and elimination organs, and plays a role in drug absorption and excretion. Increasingly, P-gp has been acknowledged as an important player in potential DDIs and a growing body of information on the role of this transporter in DDIs has become available from research and from the drug approval process. This has led to a clear need for a comprehensive review of P-gp-mediated DDIs with a focus on highlighting the drugs that are likely to lead to clinically relevant DDIs. The objective of this review is to provide information for identifying and interpreting evidence of P-gp-mediated DDIs and to suggest a classification for individual drugs based on both in vitro and in vivo evidence (substrates, inhibitors and inducers). Further, various ways of handling potential DDIs in clinical practice are described and exemplified in relation to drugs interfering with P-gp. | ||
| 650 | 4 | |a Digoxin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Caco2 Cell |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Carvedilol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Apixaban |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Petersen, Tonny Studsgaard |e verfasserin |4 aut | |
| 700 | 1 | |a Dalhoff, Kim Peder |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 77(2017), 8 vom: 05. Apr., Seite 859-883 |w (DE-627)SPR033129762 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2017 |g number:8 |g day:05 |g month:04 |g pages:859-883 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40265-017-0729-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 77 |j 2017 |e 8 |b 05 |c 04 |h 859-883 | ||